Managed Access Program for Del-zota in DMD Patients Announced by Avidity Biosciences
Avidity Biosciences has launched Managed Access Program for delpacibart zotadirsen (AOC 1044) targeting DMD mutations suitable for exon 44 skipping.
Therapeutic Area
Therapeutic area intelligence for Duchenne Muscular Dystrophy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.